Digest Network Come funziona
Network
/
Società
Me
Non verificato

Merck & Co., Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

233 comunicati stampa

Guarda tutti i comunicati
08/09/2026
Eventi
Web e Social Network
Biotecnologia
Sanità
Farmaceutica
Salute
Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
02/09/2026
Eventi
Web e Social Network
Biotecnologia
Sanità
Farmaceutica
Salute
Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
19/08/2026
Industria
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Scienza
Medicina - Varie
Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
06/08/2026
Industria
Scienza
HIV, AIDS e malattie autoimmuni
Infanzia
Igiene alimentare
Medicina - Varie
Biotecnologia
Farmaceutica
Vetrine/Shopping
Salute
U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
04/08/2026
Mercato azionario
Eventi
Web e Social Network
Telefonia e Varie
Veterinaria
HIV, AIDS e malattie autoimmuni
Igiene alimentare
Medicina - Varie
Cardiologia
Biotecnologia
Salute
Farmaceutica
Oncologia
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
29/07/2026
Titoli e azioni
Biotecnologia
Sanità
Farmaceutica
Salute
Merck Announces Fourth-Quarter 2026 Dividend
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
24/07/2026
Industria
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
16/07/2026
Industria
Scienza
Igiene alimentare
Fitness
Medicina - Varie
Cardiologia
Biotecnologia
Sanità
Farmaceutica
Salute
Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
15/07/2026
Web e Social Network
Telefonia e Varie
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
HIV, AIDS e malattie autoimmuni
Salute
Igiene alimentare
Medicina - Varie
Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
15/07/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0